Healthcare
•3759 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (3759)
| Company | Market Cap | Price |
|---|---|---|
|
BDX
Becton, Dickinson and Company
BD is a global medical devices & biometrics company with multiple device-based offerings and biometric sensing capabilities.
|
$57.58B |
$201.06
+0.08%
|
|
IDXX
IDEXX Laboratories, Inc.
IDEXX manufactures in-clinic diagnostic instruments and related software (e.g., VetLab analyzers, Catalyst) and provides point-of-care diagnostics.
|
$56.34B |
$699.46
-0.67%
|
|
MET
MetLife, Inc.
Health Insurance is offered as part of Group Benefits/employee benefits.
|
$54.64B |
$82.82
+0.80%
|
|
ZTS
Zoetis Inc.
Zoetis markets vaccines for companion animals and livestock, a major revenue and product category.
|
$52.59B |
$120.91
+1.90%
|
|
ARGX
argenx SE
argenx's core offerings are monoclonal antibody therapeutics, including VYVGART.
|
$52.50B |
$846.03
-3.63%
|
|
ALNY
Alnylam Pharmaceuticals, Inc.
Alnylam's core product modality is RNA interference (RNAi) therapeutics, including approved products AMVUTTRA, ONPATTRO, GIVLAARI, and OXLUMO.
|
$52.11B |
$394.29
-0.82%
|
|
EW
Edwards Lifesciences Corporation
Core product category including SAPIEN/TAVR, Pascal, Evoque, and SAPIEN M3 used in structural heart interventions.
|
$48.78B |
$83.47
+0.47%
|
|
ROP
Roper Technologies, Inc.
Verathon bronchoscopes and other medical devices place Roper squarely in Medical Devices & Biometrics.
|
$47.98B |
$444.67
-0.27%
|
|
CAH
Cardinal Health, Inc.
Nuclear medicine radiopharmaceuticals distribution and related imaging agents.
|
$47.32B |
$199.49
+0.66%
|
|
AME
AMETEK, Inc.
Paragon Medical alignment indicates AMETEK provides Medical Device Components as part of its Electromechanical Group.
|
$46.59B |
$203.09
+0.67%
|
|
TAK
Takeda Pharmaceutical Company Limited
Takeda is a large-cap pharmaceutical company with a diversified, high-revenue drug portfolio and pipeline.
|
$45.43B |
$14.55
+1.57%
|
|
HLN
Haleon plc
Panadol and other analgesics position Haleon in OTC Pain Relief & Analgesics.
|
$43.47B |
$9.81
+3.10%
|
|
INSM
Insmed Incorporated
Brensocatib is an oral small molecule therapeutic targeting DPP1, a core part of Insmed's pipeline.
|
$41.64B |
$196.30
-0.36%
|
|
PAYX
Paychex, Inc.
Health Insurance; PEO insurance solutions for employees.
|
$41.59B |
$115.84
+0.34%
|
|
PUK
Prudential plc
Health insurance offerings are a central pillar of Prudential's business strategy and geographic footprint.
|
$40.06B |
$29.91
+2.78%
|
|
A
Agilent Technologies, Inc.
Agilent provides diagnostic instrument platforms used in life sciences and clinical diagnostics.
|
$39.68B |
$140.31
+0.45%
|
|
ALC
Alcon Inc.
Alcon directly designs and manufactures ophthalmology devices including intraocular lenses and surgical platforms.
|
$38.97B |
$79.14
+0.43%
|
|
GEHC
GE HealthCare Technologies Inc.
GE HealthCare's core product portfolio centers on medical imaging devices and imaging systems (CT/MR/PET).
|
$38.33B |
$84.43
+0.56%
|
|
IQV
IQVIA Holdings Inc.
IQVIA operates as outsourced drug development and clinical research services akin to a CRO.
|
$37.78B |
$224.10
+0.83%
|
|
RMD
ResMed Inc.
CPAP devices and masks are core ResMed medical devices.
|
$36.94B |
$251.68
-0.24%
|
|
BBD
Banco Bradesco S.A.
Health insurance products within Bradesco's Insurance Group.
|
$36.72B |
$3.48
+0.72%
|
|
VTR
Ventas, Inc.
Healthcare Services & Facilities captures ownership/operation of healthcare facilities including senior housing and outpatient spaces.
|
$35.39B |
$78.78
+1.18%
|
|
ONC
BeOne Medicines Ltd.
Core oncology-focused biotech; primary business segment is oncology therapeutics.
|
$35.14B |
$309.05
-3.14%
|
|
SLF
Sun Life Financial Inc.
Health insurance offerings (including group health solutions and stop-loss) are key to Sun Life's business.
|
$34.79B |
$60.97
+0.93%
|
|
KVUE
Kenvue Inc.
Kenvue directly manufactures and sells OTC analgesics (e.g., Tylenol).
|
$33.26B |
$17.29
-0.26%
|
|
HUM
Humana Inc.
Humana's core revenue and offerings are health insurance products and related services for individuals, employers, and government programs.
|
$32.29B |
$274.21
+2.15%
|
|
NTRA
Natera, Inc.
Natera's Signatera MRD and Signatera Genome tests are liquid biopsy assays using cfDNA to detect minimal residual disease in cancer, a core liquid biopsy product.
|
$31.83B |
$228.79
-1.36%
|
Showing page 3 of 38 (3759 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
